Report an error

Spotted something inaccurate in “Selective D1/D5 Agonist Tavapadon Extends Parkinson's On-Time in Phase 3 Trial”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.